Stock Track | Harrow Health Soars 30% on Strong Q4 Results and Optimistic 2025 Outlook

Stock Track03-18

Harrow Health Inc (HROW) shares skyrocketed 30.16% in pre-market trading on Tuesday, following the company's announcement of better-than-expected preliminary fourth-quarter results and a positive outlook for 2025. The eye-care pharmaceutical company's strong performance has significantly boosted investor confidence.

According to the preliminary results released after Monday's closing bell, Harrow expects to report a profit of $5 million to $7 million on revenue of $65 million to $67 million for the fourth quarter. This forecast substantially outperforms Wall Street's expectations, as analysts had anticipated a fourth-quarter loss of $300,000 on sales of $58.4 million. The company's ability to turn an expected loss into a substantial profit has clearly impressed investors.

Adding to the positive sentiment, Harrow's Chief Executive Mark Baum provided an initial 2025 outlook, projecting revenue of over $280 million for the year. This projection aligns closely with analysts' models, which predicted sales of $281.2 million. While the company has delayed the release of its audited financial statements due to its new auditor requiring additional time, CEO Baum reassured investors of the company's commitment to comprehensive, accurate, and transparent financial reporting. The strong Q4 results, combined with the optimistic future outlook, have contributed to the substantial pre-market rally, making Harrow Health one of the top pre-market gainers in the health care sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1167517712?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-18 21:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167517712","market":"hk","top_or_hot":-1,"title":"Stock Track | Harrow Health Soars 30% on Strong Q4 Results and Optimistic 2025 Outlook","media":"Stock Track","content":"<p>Harrow Health Inc (HROW) shares skyrocketed 30.16% in pre-market trading on Tuesday, following the company's announcement of better-than-expected preliminary fourth-quarter results and a positive outlook for 2025. The eye-care pharmaceutical company's strong performance has significantly boosted investor confidence.</p>\n\n<p>According to the preliminary results released after Monday's closing bell, Harrow expects to report a profit of $5 million to $7 million on revenue of $65 million to $67 million for the fourth quarter. This forecast substantially outperforms Wall Street's expectations, as analysts had anticipated a fourth-quarter loss of $300,000 on sales of $58.4 million. The company's ability to turn an expected loss into a substantial profit has clearly impressed investors.</p>\n\n<p>Adding to the positive sentiment, Harrow's Chief Executive Mark Baum provided an initial 2025 outlook, projecting revenue of over $280 million for the year. This projection aligns closely with analysts' models, which predicted sales of $281.2 million. While the company has delayed the release of its audited financial statements due to its new auditor requiring additional time, CEO Baum reassured investors of the company's commitment to comprehensive, accurate, and transparent financial reporting. The strong Q4 results, combined with the optimistic future outlook, have contributed to the substantial pre-market rally, making Harrow Health one of the top pre-market gainers in the health care sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Harrow Health Soars 30% on Strong Q4 Results and Optimistic 2025 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Harrow Health Soars 30% on Strong Q4 Results and Optimistic 2025 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-18 21:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Harrow Health Inc (HROW) shares skyrocketed 30.16% in pre-market trading on Tuesday, following the company's announcement of better-than-expected preliminary fourth-quarter results and a positive outlook for 2025. The eye-care pharmaceutical company's strong performance has significantly boosted investor confidence.</p>\n\n<p>According to the preliminary results released after Monday's closing bell, Harrow expects to report a profit of $5 million to $7 million on revenue of $65 million to $67 million for the fourth quarter. This forecast substantially outperforms Wall Street's expectations, as analysts had anticipated a fourth-quarter loss of $300,000 on sales of $58.4 million. The company's ability to turn an expected loss into a substantial profit has clearly impressed investors.</p>\n\n<p>Adding to the positive sentiment, Harrow's Chief Executive Mark Baum provided an initial 2025 outlook, projecting revenue of over $280 million for the year. This projection aligns closely with analysts' models, which predicted sales of $281.2 million. While the company has delayed the release of its audited financial statements due to its new auditor requiring additional time, CEO Baum reassured investors of the company's commitment to comprehensive, accurate, and transparent financial reporting. The strong Q4 results, combined with the optimistic future outlook, have contributed to the substantial pre-market rally, making Harrow Health one of the top pre-market gainers in the health care sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HROW","symbol_name":"Harrow Health Inc","start_time":0,"source_url":"","article_id":"1167517712","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167517712","pubTimestamp":1742304893,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Harrow Health Inc  shares skyrocketed 30.16% in pre-market trading on Tuesday, following the company's announcement of better-than-expected preliminary fourth-quarter results and a positive outlook for 2025. The eye-care pharmaceutical company's strong performance has significantly boosted investor confidence.Adding to the positive sentiment, Harrow's Chief Executive Mark Baum provided an initial 2025 outlook, projecting revenue of over $280 million for the year. This projection aligns closely w","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HROW":"Harrow Health Inc"},"translate_title":"股票轨迹Harrow Health因强劲的第四季度业绩和乐观的2025年前景而飙升30%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HROW":1},"content_text":"Harrow Health Inc (HROW) shares skyrocketed 30.16% in pre-market trading on Tuesday, following the company's announcement of better-than-expected preliminary fourth-quarter results and a positive outlook for 2025. The eye-care pharmaceutical company's strong performance has significantly boosted investor confidence.\nAccording to the preliminary results released after Monday's closing bell, Harrow expects to report a profit of $5 million to $7 million on revenue of $65 million to $67 million for the fourth quarter. This forecast substantially outperforms Wall Street's expectations, as analysts had anticipated a fourth-quarter loss of $300,000 on sales of $58.4 million. The company's ability to turn an expected loss into a substantial profit has clearly impressed investors.\nAdding to the positive sentiment, Harrow's Chief Executive Mark Baum provided an initial 2025 outlook, projecting revenue of over $280 million for the year. This projection aligns closely with analysts' models, which predicted sales of $281.2 million. While the company has delayed the release of its audited financial statements due to its new auditor requiring additional time, CEO Baum reassured investors of the company's commitment to comprehensive, accurate, and transparent financial reporting. The strong Q4 results, combined with the optimistic future outlook, have contributed to the substantial pre-market rally, making Harrow Health one of the top pre-market gainers in the health care sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1167517712"}